📊 GANX Key Takeaways
Is Gain Therapeutics, Inc. (GANX) a Good Investment?
Gain Therapeutics is a pre-commercial stage biopharmaceutical company with essentially zero revenue ($305K) and significant operating losses (-$5.4M). While the balance sheet shows adequate liquidity and minimal debt providing ~3+ years of cash runway, the complete absence of commercial validation, extreme negative margins (-1837.5% net margin), and ongoing cash burn of $4.7M annually make this fundamentally uninvestable based on current financials. Clinical success is required to justify investment.
Gain Therapeutics shows very weak operating fundamentals, with minimal revenue, deeply negative margins, and annualized cash burn that is large relative to its asset and equity base. The balance sheet is not heavily levered and liquidity ratios are acceptable today, but the company’s cash position appears limited against continued operating losses, making future funding needs a central concern. Fundamental improvement depends on materially reducing burn or achieving meaningful clinical and commercial progress.
Gain Therapeutics, Inc. Key Strengths (GANX)
- Strong balance sheet with $16.5M cash and only $373.5K long-term debt
- Excellent liquidity position with 4.69x current ratio providing runway for development
- Minimal debt burden (0.03x debt-to-equity ratio) limits financial risk
- Low balance-sheet leverage with debt/equity of 0.07x
- Cash of $8.81M provides near-term liquidity support
- Current and quick ratios of 2.52x indicate no immediate working-capital stress
GANX Stock Risks: Gain Therapeutics, Inc. Investment Risks
- Pre-revenue stage with $305K revenue generating minimal cash flow coverage
- Severe cash burn of $4.7M annually with negative operating cash flow
- Extreme negative profitability across all metrics (-1837.5% net margin, -40% ROE)
- Zero revenue growth YoY and no evidence of commercial traction
- No visibility to profitability; cash runway finite despite adequate current position
- Revenue base is negligible at $305.24K, indicating weak current business scale
- Operating loss of $14.24M and free cash flow of negative $13.87M imply unsustainable burn without new funding
- Negative ROE of -264.4% and ROA of -142.4% reflect severe capital inefficiency
Key Metrics to Watch
- Clinical trial progress and pipeline advancement announcements
- Revenue growth trajectory and rate of increase from near-zero baseline
- Monthly cash burn rate and remaining runway
- Operating cash flow trend toward breakeven
- Quarterly operating cash burn relative to cash balance
- Any sustained revenue growth or milestone-driven improvement in operating loss
Gain Therapeutics, Inc. (GANX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.69x current ratio provides a solid financial cushion.
GANX Profit Margin, ROE & Profitability Analysis
GANX vs Healthcare Sector: How Gain Therapeutics, Inc. Compares
How Gain Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Gain Therapeutics, Inc. Stock Overvalued? GANX Valuation Analysis 2026
Based on fundamental analysis, Gain Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Gain Therapeutics, Inc. Balance Sheet: GANX Debt, Cash & Liquidity
GANX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Gain Therapeutics, Inc.'s revenue has declined by 59% over the 5-year period, indicating business contraction. The most recent EPS of $-0.89 indicates the company is currently unprofitable.
GANX Revenue Growth, EPS Growth & YoY Performance
GANX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $55.2K | -$4.5M | $-0.17 |
| Q2 2024 | $55.2K | -$7.7M | $-0.42 |
| Q1 2024 | $55.2K | -$4.0M | $-0.22 |
| Q3 2023 | $55.2K | -$4.6M | $-0.37 |
| Q2 2023 | $55.2K | -$5.1M | $-0.43 |
| Q1 2023 | $37.5K | -$3.3M | $-0.28 |
| Q3 2022 | $16.0K | -$4.6M | $-0.38 |
| Q2 2022 | $81.6K | -$3.6M | $-0.30 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Gain Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
GANX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Gain Therapeutics, Inc. (CIK: 0001819411)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GANX
What is the AI rating for GANX?
Gain Therapeutics, Inc. (GANX) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GANX's key strengths?
Claude: Strong balance sheet with $16.5M cash and only $373.5K long-term debt. Excellent liquidity position with 4.69x current ratio providing runway for development. ChatGPT: Low balance-sheet leverage with debt/equity of 0.07x. Cash of $8.81M provides near-term liquidity support.
What are the risks of investing in GANX?
Claude: Pre-revenue stage with $305K revenue generating minimal cash flow coverage. Severe cash burn of $4.7M annually with negative operating cash flow. ChatGPT: Revenue base is negligible at $305.24K, indicating weak current business scale. Operating loss of $14.24M and free cash flow of negative $13.87M imply unsustainable burn without new funding.
What is GANX's revenue and growth?
Gain Therapeutics, Inc. reported revenue of $305.2K.
Does GANX pay dividends?
Gain Therapeutics, Inc. does not currently pay dividends.
Where can I find GANX SEC filings?
Official SEC filings for Gain Therapeutics, Inc. (CIK: 0001819411) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GANX's EPS?
Gain Therapeutics, Inc. has a diluted EPS of $-0.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is GANX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Gain Therapeutics, Inc. has a C grade with 84% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is GANX stock overvalued or undervalued?
Valuation metrics for GANX: ROE of -40.0% (sector avg: 15%), net margin of -1,837.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is GANX's AI grade for 2026?
Our dual AI analysis gives Gain Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GANX's free cash flow?
Gain Therapeutics, Inc.'s operating cash flow is $-4.7M, with capital expenditures of $22.5K. FCF margin is -1,556.2%.
How does GANX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,837.5% (avg: 12%), ROE -40.0% (avg: 15%), current ratio 4.69 (avg: 2).